12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sofosbuvir regulatory update

Gilead submitted an NDA to FDA for sofosbuvir to treat chronic HCV infection. The company said the application covers the use of sofosbuvir in combination with ribavirin...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >